AstraZeneca and Peregrine Pharmaceuticals Inc. entered into a cancer immunotherapy clinical trial collaboration.
FDA and the European Medicines Agency accepted regulatory applications for Gilotrif (afatinib), sponsored by Boehringer Ingelheim, for the treatment of advanced squamous cell carcinoma of the lung, after treatment with first-line chemotherapy.
BTG plc of London said that Wellstat Therapeutics' new drug application for uridine triacetate has been accepted for review by FDA.
Can-Fite BioPharma Ltd. of Petach Tikva, Israel, said FDA has granted the company's drug candidate CF102 Fast Track designation as a second line treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer. CF102 had already received the FDA's Orphan Drug designation.
AbbVie has submitted a supplemental New Drug Application to FDA based on the randomized, multi-center, open-label phase III RESONATE trial of IMBRUVICA (ibrutinib) versus chlorambucil in treatment-naive chronic lymphocytic leukemia patients aged 65 years or older.
DAN JONES and ANIL PARWANI were recruited to serve in leadership roles for specialized pathology services offered across The Ohio State University Wexner Medical Center.
NCI has funded five research teams to participate in its Pediatric Preclinical Testing Consortium.
President Barack Obama nominated Robert Califf to the post of Commissioner of Food and Drugs.
MD ANDERSON CANCER CENTER and Esperance Pharmaceuticals Inc. entered into a strategic alliance to accelerate the clinical development of its lead anti-cancer candidate, EP-100, for the treatment of ovarian cancer, and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.
NCI is planning to increase funding for the Cancer Center Core Grants, Acting Director Douglas Lowy said to the National Cancer Advisory Board at a meeting Sept. 16.
